CRA Celera Corporation featured news, full reports, and detailed charts
Celera Corporation (CRA) Wrap Up:
Relationship with Applied Biosystems, Inc. Prior to July 1, 2008, we were a wholly owned business segment of Applied Biosystems, Inc. (Applied Biosystems), formerly known as Applera Corporation (Applera). Since 1999, the relative performance of Celera Corporation (Celera) has been reflected by the Celera Group tracking stock, a class of common stock of Applied Biosystems. On May 8, 2008, Applied Biosystems’ Board of Directors approved the split-off of the Celera Group into an independent company. The split-off was effective on July 1, 2008, when each holder of Celera Group tracking stock received one share of Celera Corporation common stock. Celera Corporation common stock is listed on the NASDAQ Stock Market under the symbol “CRA.” As a result of the split-off, we are now an independent public company. We will continue to have contractual and commercial relationships with Applied Biosystems. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f09%2f08%2f0001193125-08-191561.html#FIS_BUSINESS"Celera Corporation (CRA:NASDAQ)
Snapshot of Celera Corporation (CRA)
|
OPEN
$6.27
|
PREVIOUS CLOSE
$6.30
|
|
|
DAY HIGH
$6.30
|
DAY LOW
$6.21
|
|
|
52 WEEK HIGH
01/6/09 - $11.71
|
52 WEEK LOW
03/17/09 - $5.03
|
|
|
MARKET CAP
508.9M
|
AVERAGE VOLUME 3 mo
430.7K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
81.9M
|
|
|
CRA Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
What Wall Street analysts are saying about selected stocks in the news Monday
CRA Top Compensated Officers
Executives, Board Directors
Key developments for Celera Corporation (CRA)
Celera Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 26, 2009. Net revenues of $40.0 million for the third quarter of 2009 that ended September 26, 2009, compared to $45.8 million in the prior year quarter. For the third quarter of 2009, the company reported a net loss of $7.4 million, or $0.09 per share, compared to a net loss of $7.0 million, or $0.09 per share, for the prior year quarter. Operating loss was $8.8 million against $6.3 million a year ago. Loss before tax was $7.4 million against $7.0 million a year ago. For the third quarter of 2009, these items increased the net loss by $7.1 million, and included expenses associated with the previously announced restructuring program and other charges. Amortization of purchased intangible assets, employee-related charges, asset impairments, litigation-related charge and legal settlement and non-cash interest income impacts third quarter results. For the third quarter of 2008, these items increased the net loss for the quarter by $7.6 million. Excluding the items, the company's net loss on a non-GAAP basis for the third quarter of 2009 was $0.3 million, or breakeven on a per share basis, compared to net income of $0.6 million, or $0.01 per share, for the prior year quarter. Non-GAAP loss before income taxes was $0.3 million against income of $0.6 million a year ago. For the nine months period, the company reported loss before tax of $46.8 million and net loss of $40.5 million or $0.50 per basic and diluted share on net revenue of $127.1 million against loss before tax of $23.5 million and net loss of $118.5 million or $1.48 per basic and diluted share on net revenue of $128.0 million reported a year ago. Operating loss was $52.0 million against $25.9 million a year ago. Under Non-GAAP, net loss was $18.8 million or $0.23 per diluted share against net loss of $1.3 million or $0.02 per diluted share reported a year ago. Non-GAAP loss before income taxes was $18.8 million against $2.4 million a year ago. For the fourth quarter of 2009, the company anticipates a net loss of $4-$6 million, or $0.05-$0.07, on a non-GAAP basis. For the year 2009, total revenues are anticipated to be $163-$167 million, the same mid-point as prior guidance of $160-$170 million. Gross margin, as a percentage of revenue, is anticipated to be 66-70%.
Celera Corporation, Q3 2009 Earnings Call, Oct 28 2009
Celera Corporation expected to Report Fiscal Year 2009 Results on February 15, 2010. This event was calculated by Capital IQ (Created on October 21, 2009).
CRA Competitors
| Company | Last | Change |
| ABAXIS Inc | $22.52 USD | -0.06 |
| Genomic Health Inc | $19.03 USD | -0.01 |
| Luminex Corporation | $13.77 USD | +0.13 |
| Quidel Corp | $13.29 USD | +0.02 |
| ZymoGenetics Inc | $5.72 USD | -0.02 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CRA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.1x |
|
| Price/Book | 0.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.1x |
|
|
CRA |
||
CRA transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
